Skin Cancer News and Research RSS Feed - Skin Cancer News and Research

Skin cancer is the most common type of cancer in the U.S. It occurs in more than a million people each year, including many older people. There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Of the three, melanoma is the most serious. Skin cancer occurs when abnormal cells form and multiply in an uncontrolled way in the epidermis, or abnormal cells from the epidermis invade the dermis of the skin. Basal cell carcinoma, squamous cell carcinoma, and melanoma are skin cancers that are named for the epidermal cells from which they develop.
New web-based platform launched to provide acne care to patients across Pennsylvania

New web-based platform launched to provide acne care to patients across Pennsylvania

Dr. Jamie Altman, owner and president of Aesthetic Dermatology Associates, PC, a dermatology practice based in the Philadelphia suburbs of Media and Paoli, today announced the launch of AcneCareMD.com, a secure telemedicine website designed to provide acne care to patients across Pennsylvania via a web-based platform. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Preventable deaths caused by acute kidney injury (AKI) could be nearly eliminated in just 10 years, according to leading medical experts. This often forgotten condition - which affects around 13 million people every year and contributes to 1.7 million deaths annually - is preventable and can be treated for as little as $US150 per patient. [More]
Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened. [More]
Naproxen and omeprazole combination effective in preventing bladder cancer

Naproxen and omeprazole combination effective in preventing bladder cancer

The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds. [More]
Researchers develop improved MRI technique to provide effective treatment for prostate cancer

Researchers develop improved MRI technique to provide effective treatment for prostate cancer

A research team including NIBIB-funded scientists has developed an improved MRI technique with the potential to provide more precise and effective treatment for prostate cancer. The imaging technique improves upon standard MRI to obtain clearer images of the extent of the tumor and its exact location. A sharper image can provide more accurate biopsies, enable better treatment planning, and help surgeons pinpoint the tumor while sparing surrounding healthy tissue. [More]
Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States. [More]
Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy. [More]
New medical device could revolutionise kidney disease care in the UK

New medical device could revolutionise kidney disease care in the UK

A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the 1 million people in the UK who don’t know they have kidney disease, a new report by the Institution of Mechanical Engineers reveals today. [More]
Scientists identify promising new therapeutic target for prostate cancer

Scientists identify promising new therapeutic target for prostate cancer

Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma. [More]
MD Anderson, CATCH Global Foundation partner to lower cancer risk in children

MD Anderson, CATCH Global Foundation partner to lower cancer risk in children

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings nationwide, to promote behavior that will lower children's lifelong risk of developing cancer. [More]
Changes in moles and skin cancer: an interview with Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson

Changes in moles and skin cancer: an interview with Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson

Melanoma is the 5th most common cancer in the UK and its incidence is continuing to increase since the mid-1970s. Cancer Research UK reports that its rates have increased more rapidly than any of the current ten most common cancers in males and females.
Whilst some of this may be attributed to better surveillance and earlier detection, the real problem lies with sun-seeking behaviour and exposure to ultraviolet (UV) radiation. [More]
Moffitt physicians promote novel screening strategies to decrease melanoma mortality

Moffitt physicians promote novel screening strategies to decrease melanoma mortality

Melanoma, the most deadly type of skin cancer, was to blame for approximately 9,700 deaths in 2014. And with the number of melanoma cases increasing each year, it is believed that the disease could become one of the most common types of cancer in the United States by 2030. Promoting and developing national screening strategies may help to reduce deaths due to melanoma. [More]
New laser technology shows promise for cancer treatment

New laser technology shows promise for cancer treatment

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer. [More]
OHSU Knight Cancer Institute funds 17 community projects to decrease impact of cancer on Oregonians

OHSU Knight Cancer Institute funds 17 community projects to decrease impact of cancer on Oregonians

The Knight Cancer Institute at Oregon Health & Science University awarded $462,656 to 17 projects statewide as part of the first round of funding offered through its Community Partnership Program. The program's goal is to address community-identified needs to ultimately decrease the impact of cancer on Oregonians. [More]
FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec. [More]
Liquid Nitrogen generation: an interview with Andy Boyle, COO, MMR Technologies, Inc

Liquid Nitrogen generation: an interview with Andy Boyle, COO, MMR Technologies, Inc

Liquid Nitrogen has many uses and applications beyond that of the medical and life sciences. In addition to dermatological use, biological specimen and embryo preservation, our customers use the Elan2 for cooling the outer jackets of MRI systems, semiconductor radiation detector cooling, infrared detector cooling and cryogenic annealing of metals. [More]
Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form. [More]
Advertisement
Advertisement